Intervacc AB
The answer first
Does Intervacc beat the market?
No, Intervacc has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 18% of Nordic stocks
- Quality70
- Value15
- Trend15
No. 140 of 195 in healthcare
Max for seven days
Follow Intervacc with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Intervacc
Your first answer is free, no account needed.
Do you own Intervacc, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Intervacc and a few more. Free, no card.
Super Stock+44.6%In short
- Intervacc has fallen 28.5% over the past year, including dividends.
- Overall, Intervacc ranks better than 18% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 98.1%. The price is 99.0% below its peak now.
What do analysts think of Intervacc?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 18% of Nordic stocks.
No. 140 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 85 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.00
- Asset turnoverSales divided by everything the company owns0.07
- Return on equityProfit divided by equity−50.5%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 114 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity1.1
- P/SPrice divided by sales13.0
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 141 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−38.1%
- 6 months−45.4%
- 9 months−4.4%
- 12 months−28.5%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Intervacc
3 funds we follow own Intervacc. The share is how much of the fund the stock makes up.
- Sweden3
From the funds' latest known holdings.
About Intervacc
Intervacc AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 16 employees.
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Strangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and sheep. The company was incorporated in 1983 and is based in Hägersten, Sweden.


See the full analysis of Intervacc.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card